Pizzuti Dana's Form 4 filing
Crinetics Pharmaceuticals, Inc. (CRNX) · filed Apr 17, 2024
- Accession no.
- 0000950170-24-045142
- Filed
- Apr 17, 2024
- Trade date
- Apr 15, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $639.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Pizzuti DanaCIK 0001948238 | Officer (Chief Med and Dev Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 15, 2024 | Common Stock | MOption exerciseAcquired | +14,375 | $16.89 | +$242,793.75 | 42,161 | Direct | |
| Apr 15, 2024 | Common Stock | SSaleDisposed | −14,375 | $44.47F2 | −$639,256.25 | 27,786 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 15, 2024 | Common Stock | MOption exerciseDisposed | −14,375 | $0.00 | $0 | 177,292 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.47 per share. The range of sales prices on the transaction date was $43.98 to $44.75 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
Referenced by the price of 1 transaction in Table I.